Table of Contents
Chapter 1 Molecular Cytogenetics Market: Research Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Application Segment
1.1.1.2 Technology Segment
1.1.1.3 Product Segment
1.1.1.4 End Use Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Molecular Cytogenetics Market: Executive Summary
2.1 Market Outlook
2.2 Application And Technology Snapshot
2.3 Product And End Use Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Molecular Cytogenetics Market: Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Drivers Analysis
3.2.1.1 Rapid technological advancements
3.2.1.2 Increasing prevalence of genetic disorders
3.2.1.3 Growing application in oncology
3.2.1.4 Increasing demand for personalized medicine
3.2.2 Market Restraint Analysis
3.2.2.1 High Costs Of Testing
3.2.2.2 Lack Of Reimbursement Policies
3.3 Industry Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
Chapter 4 Molecular Cytogenetics Market: Application Business Analysis
4.1 Molecular Cytogenetics Market: Application Movement Analysis
4.2 Genetic Disorders
4.2.1 Genetic Disorders Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.3 Oncology
4.3.1 Oncology Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.4 Personalized Medicine
4.4.1 Personalized Medicine Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.5 Other Application
4.5.1 Other Application Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 5 Molecular Cytogenetics Market: Technology Business Analysis
5.1 Molecular Cytogenetics Market: Technology Movement Analysis
5.2 Comparative Genomic Hybridisation
5.2.1 Comparative Genomic Hybridisation Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2 ACGH
5.2.2.1 ACGH Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.3 SCGH
5.2.3.1 SCGH Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.3 Fish
5.3.1 Fish Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Immunohistochemistry
5.4.1 Immunohistochemistry Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5 Karyotyping
5.5.1 Karyotyping Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5.2 Spectral
5.5.2.1 Spectral Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5.3 Virtual
5.5.3.1 Virtual Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.6 Others
5.6.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Molecular Cytogenetics Market: Product Business Analysis
6.1 Molecular Cytogenetics Market: Product Movement Analysis
6.2 Instruments
6.2.1 Instruments Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.3 Consumables
6.3.1 Consumables Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.4 Software & Services
6.4.1 Software & Services Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Molecular Cytogenetics Market: End Use Business Analysis
7.1 Molecular Cytogenetics Market: End Use Movement Analysis
7.2 Clinical & Research Laboratories
7.2.1 Clinical & Research Laboratories Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3 Hospitals & Path Labs
7.3.1 Hospitals & Path Labs Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4 Academic Research Institutes
7.4.1 Academic Research Institutes Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5 Pharmaceutical & Biotech Companies
7.5.1 Pharmaceutical & Biotech Companies Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6 Others
7.6.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Molecular Cytogenetics Market: Regional Business Analysis
8.1 Regional Market Snapshot
8.2 North America
8.2.1 North America Molecular Cytogenetics Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.2.2.2 Key Country Dynamics
8.2.2.3 Regulatory Framework
8.2.2.4 Reimbursement Scenario
8.2.3 Canada
8.2.3.1 Canada Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.2.3.2 Key Country Dynamics
8.2.3.3 Regulatory Framework
8.2.3.4 Reimbursement Scenario
8.3 Europe
8.3.1 Europe Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.2 UK
8.3.2.1 UK Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.2.2 Key Country Dynamics
8.3.2.3 Regulatory Framework
8.3.2.4 Reimbursement Scenario
8.3.3 Germany
8.3.3.1 Germany Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.3.2 Key Country Dynamics
8.3.3.3 Regulatory Framework
8.3.3.4 Reimbursement Scenario
8.3.4 Spain
8.3.4.1 Spain Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.4.2 Key Country Dynamics
8.3.4.3 Regulatory Framework
8.3.4.4 Reimbursement Scenario
8.3.5 France
8.3.5.1 France Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.5.2 Key Country Dynamics
8.3.5.3 Regulatory Framework
8.3.5.4 Reimbursement Scenario
8.3.6 Italy
8.3.6.1 Italy Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.6.2 Key Country Dynamics
8.3.6.3 Regulatory Framework
8.3.6.4 Reimbursement Scenario
8.3.7 Denmark
8.3.7.1 Denmark Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.7.2 Key Country Dynamics
8.3.7.3 Regulatory Framework
8.3.7.4 Reimbursement Scenario
8.3.8 Sweden
8.3.8.1 Sweden Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.8.2 Key Country Dynamics
8.3.8.3 Regulatory Framework
8.3.8.4 Reimbursement Scenario
8.3.9 Norway
8.3.9.1 Norway Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.3.9.2 Key Country Dynamics
8.3.9.3 Regulatory Framework
8.3.9.4 Reimbursement Scenario
8.4 Asia Pacific
8.4.1 Asia-Pacific Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.2.2 Key Country Dynamics
8.4.2.3 Regulatory Framework
8.4.2.4 Reimbursement Scenario
8.4.3 China
8.4.3.1 China Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.3.2 Key Country Dynamics
8.4.3.3 Regulatory Framework
8.4.3.4 Reimbursement Scenario
8.4.4 India
8.4.4.1 India Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.4.2 Key Country Dynamics
8.4.4.3 Regulatory Framework
8.4.4.4 Reimbursement Scenario
8.4.5 South Korea
8.4.5.1 South Korea Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.5.2 Key Country Dynamics
8.4.5.3 Regulatory Framework
8.4.5.4 Reimbursement Scenario
8.4.6 Thailand
8.4.6.1 Thailand Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.6.2 Key Country Dynamics
8.4.6.3 Regulatory Framework
8.4.6.4 Reimbursement Scenario
8.4.7 Australia
8.4.7.1 Australia Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.4.7.2 Key Country Dynamics
8.4.7.3 Regulatory Framework
8.4.7.4 Reimbursement Scenario
8.5 Latin America
8.5.1 Latin America Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.5.2.2 Key Country Dynamics
8.5.2.3 Regulatory Framework
8.5.2.4 Reimbursement Scenario
8.5.3 Mexico
8.5.3.1 Mexico Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.5.3.2 Key Country Dynamics
8.5.3.3 Regulatory Framework
8.5.2.4 Reimbursement Scenario
8.5.4 Argentina
8.5.4.1 Argentina Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.5.4.2 Key Country Dynamics
8.5.4.3 Regulatory Framework
8.5.4.4 Reimbursement Scenario
8.6 MEA
8.6.1 MEA Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.6.2.2 Key Country Dynamics
8.6.2.3 Regulatory Framework
8.6.2.4 Reimbursement Scenario
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.6.3.2 Key Country Dynamics
8.6.3.3 Regulatory Framework
8.6.3.4 Reimbursement Scenario
8.6.4 UAE
8.6.4.1 UAE Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.6.4.2 Key Country Dynamics
8.6.4.3 Regulatory Framework
8.6.2.4 Reimbursement Scenario
8.6.5 Kuwait
8.6.5.1 Kuwait Molecular Cytogenetics Market, 2018 – 2030 (USD Million)
8.6.5.2 Key Country Dynamics
8.6.5.3 Regulatory Framework
8.6.5.4 Reimbursement Scenario
Chapter 9 Molecular Cytogenetics Market: Competitive Landscape
9.1 Company Categorization
9.2 Strategy Mapping
9.2.1 New product launch
9.2.2 Partnerships
9.2.3 Acquisition
9.2.4 Collaboration
9.2.5 Funding
9.3 Company Market Share Analysis, 2022
9.4 Company Profiles
9.4.1 BIOVIEW
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 DANAHER
9.4.2.1 Company overview
9.4.2.1.1 Leica Biosystems Nussloch GmbH
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 METASYSTEMS
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 AGILENT TECHNOLOGIES, INC.
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product benchmarking
9.4.4.4 Strategic initiatives
9.4.5 ABBOTT
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product benchmarking
9.4.5.4 Strategic initiatives
9.4.6 BIO-RAD LABORATORIES, INC.
9.4.6.1 Company overview
9.4.6.2 Financial performance
9.4.6.3 Product benchmarking
9.4.6.4 Strategic initiatives
9.4.7 ILLUMINA, INC.
9.4.7.1 Company overview
9.4.7.2 Financial performance
9.4.7.3 Product benchmarking
9.4.7.4 Strategic initiatives
9.4.8 OXFORD GENE TECHNOLOGY
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
9.4.9 F. HOFFMANN-LA ROCHE LTD
9.4.9.1 Company overview
9.4.9.1.1 Genentech, Inc.
9.4.9.2 Financial performance
9.4.9.4 Product benchmarking
9.4.9.5 Strategic initiatives
9.4.10 PERKINELMER INC.
9.4.10.1 Company overview
9.4.10.2 Financial performance
9.4.10.3 Product benchmarking
9.4.10.4 Strategic initiatives
9.4.11 QUEST DIAGNOSTICS INCORPORATED
9.4.11.1 Company overview
9.4.11.1.1 Sonora Quest Laboratories
9.4.11.2 Financial performance
9.4.11.3 Product benchmarking
9.4.11.4 Product benchmarking
9.4.11.5 Strategic initiatives
9.4.12 APPLIED SPECTRAL IMAGING
9.4.12.1 Company overview
9.4.12.2 Financial performance
9.4.12.3 Product benchmarking
9.4.12.4 Strategic initiatives
9.4.13 BIOLOGICAL INDUSTRIES USA, INC.
9.4.13.1 Company overview
9.4.13.2 Financial performance
9.4.13.3 Product benchmarking
9.4.13.4 Strategic initiatives
9.4.14 CYTOTEST
9.4.14.1 Company overview
9.4.14.2 Financial performance
9.4.14.3 Product benchmarking
9.4.14.4 Strategic initiatives
9.4.15 CYTOGNOMIX
9.4.15.1 Company overview
9.4.15.2 Financial performance
9.4.15.3 Product benchmarking
9.4.16 GENIAL GENETICS
9.4.16.1 Company overview
9.4.16.2 Financial performance
9.4.16.3 Product benchmarking
9.4.16.4 Strategic initiatives
9.4.17 DIAGNOSTIC CYTOGENETICS, INC. (DCI)
8.4.17.1 Company overview
8.4.17.2 Financial performance
8.4.17.3 Product benchmarking
Chapter 10 KOL Recommendations/Analyst Perspective
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer